NEUMORA THERAPEUTICS, INC.

Highlights Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
9.9 ^USD	+2.17%		+7.96%	-41.94%

May. 14	Transcript : Neumora Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	May. 14	CI
Neumora Therapeutics Shares Fall as Q1 Loss Narrows	May. 07	MT
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Sector Update: Health Care	Apr. 15	MT
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	Apr. 15	MT
Neumora Therapeutics' Phase 1 Trial of Potential Brain Disease Drug on Hold After Convulsions in Rabbits	Apr. 15	MT
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	Apr. 15	CI
Neumora Therapeutics Q4 Loss Narrows	Mar. 07	MT
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Neumora Therapeutics, Inc. Reported Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study	Nov. 27	CI
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation	23-09-18	RE
Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million.	23-09-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer